These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25178814)

  • 1. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.
    Altarifi AA; Yuan Y; Zhang Y; Selley DE; Negus SS
    Psychopharmacology (Berl); 2015 Feb; 232(4):815-24. PubMed ID: 25178814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
    Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
    Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.
    Altarifi AA; Rice KC; Negus SS
    Behav Pharmacol; 2013 Sep; 24(5-6):459-70. PubMed ID: 23881045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.
    Moerke MJ; Negus SS
    Neuropharmacology; 2019 Jun; 151():180-188. PubMed ID: 30880123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor.
    Siemian JN; Obeng S; Zhang Y; Zhang Y; Li JX
    J Pharmacol Exp Ther; 2016 Jun; 357(3):509-19. PubMed ID: 27056847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
    Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y
    Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.
    Altarifi AA; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2015 Feb; 352(2):208-17. PubMed ID: 25406170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence.
    Altarifi AA; Negus SS
    Behav Pharmacol; 2011 Oct; 22(7):663-73. PubMed ID: 21921839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of repeated kappa-opioid receptor agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats.
    Faunce KE; Banks ML
    Exp Clin Psychopharmacol; 2020 Feb; 28(1):44-54. PubMed ID: 31008640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.
    Negus SS; Morrissey EM; Rosenberg M; Cheng K; Rice KC
    Psychopharmacology (Berl); 2010 Jun; 210(2):149-59. PubMed ID: 20101391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.
    Yuan Y; Elbegdorj O; Beletskaya IO; Selley DE; Zhang Y
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5045-8. PubMed ID: 23948248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal parameters of enhanced opioid reward after initial opioid exposure in rats.
    Moerke MJ; Negus SS
    Psychopharmacology (Berl); 2021 Mar; 238(3):725-734. PubMed ID: 33410983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
    Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
    Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
    Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
    Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the neuropeptide S receptor antagonist RTI-118 on abuse-related facilitation of intracranial self-stimulation produced by cocaine and methylenedioxypyrovalerone (MDPV) in rats.
    Bonano JS; Runyon SP; Hassler C; Glennon RA; Stevens Negus S
    Eur J Pharmacol; 2014 Nov; 743():98-105. PubMed ID: 25220242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
    Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
    Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.
    Pagare PP; Obeng S; Huang B; Marcus MM; Nicholson KL; Townsend AE; Banks ML; Zhang Y
    ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1197-1209. PubMed ID: 36407950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
    Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
    Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with mu opioid agonists.
    Easterling KW; Holtzman SG
    J Pharmacol Exp Ther; 1997 Apr; 281(1):188-99. PubMed ID: 9103497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.